Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?

Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503 | DOI:10.23822/EurAnnACI.1764-1489.261

Source: European Annals of Allergy and Clinical Immunology - July 19, 2022 Category: Allergy & Immunology Authors: E T Korkmaz O Ayd ın D Mungan B A Sin Y S Demirel S Bavbek Source Type: research